Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
aTyr Pharma Inc is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. aTyr Pharma employs 49 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.85 |
|---|---|
| 52-week range | $2.60 - $13.10 |
| 50-day moving average | $3.23 |
| 200-day moving average | $6.14 |
| Wall St. target price | $17.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.72 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.85 from 2022-07-01
| 1 week (2022-06-28) | 1.42% |
|---|---|
| 1 month (2022-06-01) | 2.15% |
| 3 months (2022-04-04) | -49.20% |
| 6 months (2022-01-03) | -62.20% |
| 1 year (2021-07-02) | -41.12% |
|---|---|
| 2 years (2020-07-02) | -33.10% |
| 3 years (2019-07-05) | 5.0463 |
| 5 years (2017-07-03) | 3.15 |
| Revenue TTM | $2.1 million |
|---|---|
| Gross profit TTM | $-23,264,000 |
| Return on assets TTM | -30.64% |
| Return on equity TTM | -52.43% |
| Profit margin | 0% |
| Book value | $3.51 |
| Market capitalisation | $80 million |
TTM: trailing 12 months
We're not expecting aTyr Pharma to pay a dividend over the next 12 months.
aTyr Pharma's shares were split on a 1:14 basis on 30 June 2019. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.
Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $2.6 up to $13.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 1.569. This would suggest that aTyr Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
aTyr Pharma, Inc. , a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co. , Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.